word count: 237 Text word count: 5807 Abstract Background: Tissue factor pathway inhibitor (TFPI) antibodies, which have been reported in patients with antiphospholipid syndrome (APS), may impair TFPI activity and contribute to hypercoagulability, but their role in APS and in thrombosis remains undefined. Objective/Methods: We assessed the presence and avidity of TFPI IgG antibodies, associations with protein C IgG antibodies and associations with clinical disease severity, in 50 patients with thrombotic APS and 50 thrombotic control patients, on long term anticoagulation with warfarin.
Introduction
Patients with thrombotic antiphospholipid syndrome (APS) inherently differ from other patients with venous or arterial thrombosis due to the presence of antiphospholipid antibodies (aPL), which are known to interfere with a number of haemostatic mechanisms. In vitro and animal studies provide evidence of the thrombogenic potential of aPL (1) (2) (3) (4) (5) (6) (7) . In animal models of thrombosis, both polyclonal (isolated from APS patients), and monoclonal (human and murine) aPL have been shown to enhance thrombus formation (3;5;6) . Human derived aPL have also been shown to be directly pathogenic in thrombosis and pregnancy morbidity (8;9) .
It has been proposed that activation or upregulation of the tissue factor (TF) pathway is integral to the hypercoagulable state observed in APS, (10) (11) (12) mainly due todown regulation of its principal inhibitor, tissue factor pathway inhibitor (TFPI) (12) (13) (14) .
Many in vitro studies have shown aPL (and specifically anti-β2 glycoprotein-1 antibodies; aβ2GPI) mediate the activation of endothelial cells with upregulation of TF expression, both at mRNA and protein level, along with inflammatory cytokines and adhesion molecules (2;5;7;15-17) ; aβ2GPI has also been shown to suppress TFPI dependent inhibition of the TF pathway of coagulation (13) . Several studies have reported the presence of TFPI antibodies in APS patients (12;18-21) , suggesting a possible contributory role in the upregulation of the TF pathway of coagulation and the observed hypercoagulability. However, the role of TFPI antibodies in APS or associations with the severity of the clinical APS phenotype is unclear. Associations with protein C antibodies, which we have shown to be associated with increased acquired protein C resistance and a more severe APS thrombotic phenotype (22) , are unknown. Accurate definition of TFPI and protein C
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The aim of this cross-sectional study was to evaluate the presence and avidity of TFPI IgG antibodies, associations with protein C IgG antibodies and also with clinical disease severity, in a well characterised cohort of patients with thrombotic APS compared to thrombotic patients without APS, on long term anticoagulation with warfarin.
Methods

Subjects and blood samples
One-hundred patients (50 APS and 50 without APS, the latter referred to as thrombotic controls), with a history of venous and/or arterial thrombosis, who had received either standard or high-intensity warfarin treatment (target international normalized ratio [INR] 2.5 and 3.5, respectively) for at least six months since the thromboembolic event were recruited in this cross-sectional study. Patients on any other oral anticoagulants or low molecular weight heparin were excluded. All patients were recruited at specialist Haematology and Rheumatology outpatient clinics at University College London Hospitals (UCLH) NHS Foundation Trust. Patients were randomly recruited as they attended the clinics; APS and thrombotic control patients included in this study were subsequently selected to match mean ages between the two patient groups.
Patients with a target INR target of 3.5 comprised those with a history of recurrent strokes/transient ischemic attacks, or recurrent VTE while on therapeutic anticoagulation (23;24) . Despite the lack of an agreed published definition for the
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5 clinical severity of thrombotic APS, patients with recurrent VTE or AT are generally considered to be high risk patients (25;26) . In the current study the term 'severe thrombotic phenotype' has been used to identify patients at high risk with VTE as well as AT or recurrent thromboembolic episodes despite therapeutic anticoagulation (warfarin target INR 2.5, range 2.0-3.0) in line with our previous work (27) .
One hundred normal controls (NC) were also recruited from staff members (all tested and found to be aPL negative 
The 99 th centile was used as a cut off to define aPL positivity in thrombotic APS patients; aCL positivity was defined as: >99 th centile= >20 MPLU, and aβ2GPI positivity was defined as: >99 th centile= >20 SGu/SMu. Prothrombin time/INR was assessed with a rabbit brain thromboplastin, PT-Fibrinogen HS Plus on a TOP500
(Werfen, Warrington, UK) with an analyser-specific international sensitivity index (1.14 Chaotrophic ELISA for determination of avidity of TFPI antibodies TFPI IgG antibody avidity was assessed by introducing chaotropic conditions to the above ELISA using a method adapted from Cucnik et al (32) . All TFPI IgG antibodies positive samples were diluted 1/100 in TBS containing increasing concentrations of NaCl: 0.15, 0.25, 0.5, 1, 2, 4, and 6M and then assayed as above. To distinguish TFPI antibodies with high or low avidity, the initial binding at 0.1M NaCl was compared with binding at higher salt concentrations, and 1M NaCl was arbitrarily selected as the reference concentration. Avidity was expressed as a percentage of maximum binding at 0.1M NaCl which was arbitrarily considered as 100%. High avidity was defined as >60% of the initial binding and low avidity as <25% at 1M
NaCl. Samples >25% but <60% binding were defined as intermediate avidity.
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TFPI activity
TFPI activity was determined with an amidolytic assay (33 
Protein C antibodies and determination of avidity
The presence and avidity of protein C IgG antibodies in 77/100 patients were previously reported (22) . The remaining 23 patients (16 APS and 7 thrombotic controls) were tested using similar methodology (22) . In summary, Costar EIA/RIA high binding plates (Fisher Scientific) were coated with 10µg/mL protein C (Ceprotin, Baxter Healthcare Ltd, Norfolk, UK), test samples were diluted 1:25. Results were expressed in arbitrary units (U/mL), with reference to index plasma from a patient with high protein C antibody levels (arbitrarily assigned as 100U/mL). Non-specific binding was eliminated by subtracting the absorbance values from uncoated wells.
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Samples were considered positive for protein C antibodies if values were >99th centile of the NC (36U/mL). The avidity of protein C antibodies was assessed in a similar way to that for TFPI avidity above, by calculating the percentage of maximum binding.
Competitive inhibition assays for TFPI and Protein C IgG ELISA
Competitive inhibition experiments were used to establish whether rTFPI, protein C, or β2GPI could abolish binding of IgG antibodies in patient plasma samples to immobilized TFPI and protein C in the ELISA assays. Briefly, plasma samples from four patients, with >100U/mL for TFPI and protein C antibodies and positive for aβ2GPI) were diluted in assay buffer to a 50% maximal binding in the TFPI and protein C ELISA, as appropriate. The effects of pre-incubation (for 2 hours at room temperature) of the diluted samples with a range of TFPI, protein C, or β2GPI Competitive inhibition assays were also performed with four patient samples with > 100U/mL for protein C antibodies and positive for aβ2GPI to see whether protein C could abolish binding to immobilized β2GPI. These assays were adapted from
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Bound IgG was detected with an anti-human IgG/HRP conjugate antibody (A6029, Sigma) as described (35) .
Increasing concentrations (0-4µg/mL) of a rabbit anti-human aβ2GPI antibody (Dako) were also added in duplicate in both the TFPI and protein C ELISA and binding to the immobilized TFPI or protein C respectively was assessed. This was performed to establish possible reactivity and direct binding to the TFPI and protein C coated plates. 
Statistical analysis
Results
Subject characteristics
Mean age in NC was 43±12 years with a male/female ratio of 52/49. Patient characteristics and clinical features are presented in Table 1 and laboratory features in Table 2 . INR values and amidolytic factor X assays suggested a similar anticoagulant intensity in the two patient groups ( (26) 23 ( p=0.004), and higher levels ( Table 2) were observed in APS compared to thrombotic control patients (p=0.007, Fig 1A) . Of the 20 APS patients positive for TFPI antibodies, high avidity antibodies were detected in ten, intermediate in six and low avidity in four patients (Fig 2) . Of the nine thrombotic control patients positive for TFPI antibodies, one patient had high, one had intermediate and seven had low avidity antibodies. TFPI antibody levels were not associated with avidity in either patient group (APS; p=0.36, thrombotic controls; p= 0.60). with decreased TFPI activity were TFPI antibody positive (Fig 3) , while 20 patients with TFPI antibodies had normal TFPI activity. All 15 patients (APS and thrombotic controls) with decreased TFPI activity had a history of at least one AT episode.
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Fig 2: Avidity of TFPI antibodies in APS patients and thrombotic controls
There was a weak association between the presence of high avidity TFPI antibodies and decreased TFPI activity in APS (5/10 APS patients with high avidity TFPI IgG antibodies had decreased TFPI activity, p=0.03).
Fig 3: Association between TFPI antibodies positivity and TFPI activity levels in APS patients and thrombotic controls Horizontal broken line represents the TFPI
activity cut off value (76.7%) and vertical dotted line represents the cut off value of 60.8U/mL for TFPI antibodies.
Protein C antibodies and avidity
All patients included in this study were also tested for presence of protein C antibodies and the results are presented in 
Associations between TFPI and protein C antibodies
Eleven out of the 20 APS patients with TFPI antibodies (regardless of avidity) were also positive for protein C antibodies (either low or high avidity) and all 11 had a severe thrombotic phenotype; ( 
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Associations with severe thrombotic phenotype and aPL
Age was not a significant factor in the development of a severe thrombotic phenotype in APS patients, but was contributory in the thrombotic control patients (OR: 1.11 with 95%CI 1.02-1.21, p=0.014), with gender not having any impact on either of the two groups.
LA was associated with a severe thrombotic phenotype in APS patients (p=0.001), 
Specificity and cross reactivity of TFPI and Protein C ELISA with β2GP1
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Due to the co-existence of TFPI antibodies, protein C antibodies and aβ2GPI in a number of patients, we performed competitive inhibition assays to evaluate whether there was any cross reactivity in the two ELISAs with β2GP1, TFPI, or protein C. In the TFPI antibody ELISA, pre-incubation of rTFPI with the test sample inhibited antibody binding in all four plasma samples in a concentration dependent manner ( Fig. 4A) . Pre-incubation with β2GP1, induced less than 12% inhibition and preincubation with protein C, less than 10% inhibition, suggesting good specificity for the TFPI IgG ELISA. This was supported by the fact that serial dilutions of a rabbit polyclonal anti-human TFPI antibody demonstrated concentration dependent binding to the coated microplate, and IgG depletion of patient plasma abolished binding in the TFPI antibody ELISA (data not shown). Similarly, pre-incubation of test samples with protein C inhibited antibody binding in the protein C antibody ELISA in a concentration dependent manner (Fig. 4B) ,
whereas pre-incubation with either rTFPI or β2GP1 caused no inhibition.
B2GP1 inhibited binding to the β2GP1 immobilized on the plate in a concentration dependent manner, whereas protein C did not inhibit binding (10% inhibition at 2.5 µM) suggesting minimum cross-reactivity ( Fig 4C) .
Absorbance of increasing concentrations of a rabbit aβ2GPI IgG antibody (0-4 µg/mL) in the TFPI and protein C antibody ELISAs was below the cut-off for positivity in either ELISA suggesting no contamination of the coating antigens with β2GP1 in either of the two ELISAs ( Figure 4D ).
Discussion
In this cross-sectional study of well characterized patients, we made the novel observation that coexistence of TFPI and protein C IgG antibodies, regardless of avidity, was strongly associated with a more severe thrombotic phenotype (as This suggests that there might be a pathophysiological relationship between the two antibodies, predisposing to the development of thrombosis. We established a higher prevalence of TFPI antibodies in thrombotic APS patients (40%; 20/50) compared to thrombotic controls (18%; 9/50). We also demonstrated, for the first time, differences in avidity between the two patient groups: TFPI antibodies were predominantly high avidity in APS (50%, 10/20 of positive patients) and strongly associated with a severe thrombotic phenotype, while thrombotic control patients mainly showed low avidity antibodies (78%, 7/9 of positive patients). The avidity assays used were based on antibody binding at high ionic strength (32) , are based on previous work by our group and others (22;32;37;38) .
The high prevalence of TFPI IgG antibodies (40% of patients with thrombotic APS), was in agreement with previous studies (prevalence 28.4-65.0% (12;18;19;21) ), but we also found that their presence and antibody levels were associated with a severe thrombotic phenotype in APS patients(OR 15.2.and 1.03, respectively p<0.0001).
Notably, TFPI antibody levels were also detected in thrombotic control patients (18%, 9/50)seven of whom had a more severe thrombotic phenotype (OR: 1.09, p=0.005). This suggests that these antibodies may contribute to the overall development of thrombotic complications and might be independent of APS criteria aPL (aCL, aβ2GPI, LA), and other non-criteria aPL (4; [39] [40] [41] [42] [43] [44] [45] [46] .
TFPI function can be impaired in APS patients (12;14;47;48) and the presence of TFPI antibodies has been suggested as a contributory factor in the pathogenesis of the disease (12;14;18-20) . In our well defined APS cohort, higher levels of TFPI antibodies were also observed in APS compared to thrombotic control patients (Table1, p=0.007). These antibodies, especially when present at high levels, do not occur frequently in patients with infection-related aPL (19) ,suggesting that they are not transient and could have a distinct pathophysiological significance.
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High avidity TFPI antibodies were weakly associated with lower TFPI activity (p=0.03), suggesting an inhibitory effect on TFPI function. Previous studies showed conflicting results for TFPI antibodies and TFPI activity: Adams et al [18] reported no association between TFPI activity and antibodies with slightly higher TFPI activity in APS patients than normal controls, while other studies, using different assay methods, reported reduced TFPI activity (12;49)( or no reduction in TFPI activity in patients with LA (20) . Studies on TFPI antigen levels are also conflicting, with levels reported to be higher (50;51), and lower (52) in APS patients compared to controls.
These varying results probably reflect the nature and sensitivity of the TFPI assay employed, which of the various TFPI interactions it measures, variations in experimental reagents and conditions, small numbers of samples, and use of different assay calibrants. There is also controversy about the pool of TFPI that is measured, as most assays only detect free plasma TFPI, which accounts for just 10-50% of total body TFPI; with poor correlation between the methods currently used (53) (54) (55) . We used a two-stage assay where TF, FVIIa and FXa are inhibited by TFPI and then residual TF/FVIIa is measured in terms of FX activation, using an amidolytic substrate for FXa. However this only assesses plasma TFPI and does not take into account the endothelial surface bound TFPI pool or intracellular, releasable TFPI. Therefore, the current assays employed for either TFPI activity or antigen levels might not be a reliable indicator of the overall anticoagulant function of TFPI in each patient.
We previously have shown (22) that high avidity protein C antibodies are associated with a more severe clinical phenotype. Protein C activity levels, though decreased, were consistent with warfarin anticoagulation, and normal protein C activity was completely restored when patient samples were mixed with normal plasma (to
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24 counteract the effects of warfarin) indicating that the antibodies were not activity neutralizing, and suggesting that protein C clearance is not increased by immune complex formation (22) . In the current study we made the novel observation that the presence of both TFPI and protein C IgG antibodies, regardless of the avidity of either antibody type, is associated with a severe thrombotic phenotype in thrombotic patients regardless of APS; suggesting a possible role in the pathogenesis of thrombosis for both sets of antibodies.
Pengo et al showed that triple aPL positivity is associated with an increased risk of thrombosis (56) , however this association not present in a multivariate analysis in our cohort possibly due to the small number of patients. However, TFPI and protein C antibodies, as well as LA were all associated with a severe thrombotic phenotype in APS patients). It has not been established whether TFPI inhibition in APS patients is dependent on criteria aPL, or due to the presence of TFPI antibodies. Salemink et al, (13) showed that total IgG, aβ2GPI and aCL isolated from APS patients all increased TF-induced FXa generation in normal plasma, but this enhancing effect was lost when patient plasma was depleted of aβ2GPI or when normal plasma was depleted of β2GPI or TFPI. Lean et al (21) , also demonstrated an association between purified aβ2GPI IgG antibodies and increased thrombin generation in the presence of TFPI, suggesting a direct interaction of aβ2GPI with TFPI despite no cross-reactivity being demonstrated between antibodies against the two proteins.
Liestol (14) demonstrated that IgG fractions isolated from certain patients with LA had an inhibitory effect on the ability of recombinant TFPI and TFPI released from the endothelium by heparin, to reduce thrombin generation Coexistence of TFPI and protein C antibodies was also present in thrombotic control patients with no aPL positivity who had a more severe thrombotic phenotype)
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Our results are in agreement with reports suggesting that non-criteria aPL such as antibodies against protein C (22) , prothrombin (57) , domain I of β2GPI and annexin V (58) might also contribute to the development of thrombosis in APS patients independently from the APS criteria aPL.' More importantly, our results suggest that these antibodies might also have a distinct role in the development of thrombosis in the general population.
The use of assays that detect high avidity antibodies to specific target proteins such as β2GPI, phosphatidylserine/prothrombin, protein C and TFPI, may prove to be more specific for the prediction of the clinical course than the tests currently used for APS diagnosis. In addition, they may prove to be helpful in assessing the anticoagulant requirements of patients with thrombosis who do not fulfil the current APS laboratory criteria and aid in identification of additional patients at high risk of thrombosis. The TFPI domain(s) responsible for TFPI antibody binding also need to be established as this may lead to differential effects on thrombin generation (59) .
The strengths of our study are the well-defined and homogeneous population of patients, including a well characterized thrombotic APS population, and the inclusion of thrombotic controls. Our study has some limitations: we did not assay IgM antibodies against TFPI and protein C; we focused on IgG as these antibodies have been shown to have significant correlations with thrombosis (60;61) The chaotropic avidity method used produced valuable results, but future studies with equilibrium methods such as surface plasmon resonance could also be used to confirm our findings.In conclusion, thrombotic APS patients exhibited a high prevalence of TFPI 
